Source comparison
Mechanism-Specific Dosing for Cartilage vs Fat Loss
AOD-9604 was originally developed as the C-terminal fragment (positions 176–191) of human growth hormone. The segment responsible for lipolysis without the insulin resistance or tissue growth effects of the full molecule. Research at Monash University in the e
This comparison does not assign a generated winner or score.
- AOD-9604 was originally developed as the C-terminal fragment (positions 176–191) of human growth hormone. The segment responsible for lipolysis without the insulin resistance or tissue growth effects of the full molecule. Research at Monash University in the early 2000s demonstrated that this fragment retained growth hormone receptor binding affinity while producing none of the hyperglycaemic side effects seen with exogenous HGH.
- Cartilage repair wasn't the original target indication, but in vitro studies revealed unexpected chondrogenic activity. AOD-9604 activates the JAK2/STAT5 pathway in chondrocytes, increasing Type II collagen mRNA expression by 240–310% at doses between 100–500 mcg (measured in cell culture models). The mechanism is receptor-mediated, not metabolic. The peptide doesn't 'force' cartilage to grow, it removes the signalling block that prevents damaged chondrocytes from entering the proliferation phase.
- Fat-loss protocols typically use 500–1000 mcg daily because adipocyte lipolysis requires sustained beta-3 adrenergic receptor activation. A dose-dependent response. Cartilage repair protocols drop to 300–500 mcg because chondrocyte proliferation saturates at lower receptor occupancy levels. The limiting factor isn't peptide concentration. It's the cell cycle duration of chondrocytes themselves, which replicate every 48–72 hours under optimal signalling conditions. Administering AOD-9604 more frequently than every 48 hours doesn't accelerate repair; it maintains the signalling environment that allows repair to proceed without interruption. Research-grade peptides synthesised through small-batch production with exact amino-acid sequencing ensure consistency across repeated administrations. Critical when dosing protocols span 12–24 weeks.